Medifast (NYSE:MED) Updates Q3 2026 Earnings Guidance

Medifast (NYSE:MED) updated its third quarter 2026 earnings guidance on Monday. The company provided EPS guidance of -0.650–0.150 for the period, compared to the consensus earnings per share estimate of -0.620. The company issued revenue guidance of $60.0 million-$80.0 million, compared to the consensus revenue estimate of $68.0 million. Medifast also updated its FY 2026 guidance to -1.750–0.250 EPS.

Medifast Price Performance

Shares of MED stock traded down $0.10 on Monday, hitting $9.72. 237,876 shares of the stock traded hands, compared to its average volume of 234,604. Medifast has a 52 week low of $9.22 and a 52 week high of $15.11. The firm has a 50 day simple moving average of $11.11 and a two-hundred day simple moving average of $11.05. The firm has a market cap of $108.14 million, a price-to-earnings ratio of -5.31 and a beta of 0.65.

Medifast (NYSE:MED) last issued its earnings results on Monday, August 3rd. The specialty retailer reported ($0.28) earnings per share for the quarter, topping the consensus estimate of ($0.65) by $0.37. Medifast had a negative net margin of 5.78% and a negative return on equity of 4.80%. The company had revenue of $76.38 million during the quarter, compared to the consensus estimate of $72.70 million. Medifast has set its FY 2026 guidance at -1.750–0.250 EPS and its Q3 2026 guidance at -0.650–0.150 EPS. Sell-side analysts forecast that Medifast will post -1.97 EPS for the current year.

Wall Street Analyst Weigh In

Several analysts recently issued reports on the company. Weiss Ratings downgraded Medifast from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, May 6th. Zacks Research raised shares of Medifast from a “hold” rating to a “strong-buy” rating in a report on Monday, July 13th. One equities research analyst has rated the stock with a Strong Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Medifast currently has an average rating of “Hold” and an average price target of $12.00.

Insider Activity at Medifast

In other news, Director Scott Schlackman acquired 2,500 shares of the business’s stock in a transaction dated Monday, May 11th. The stock was purchased at an average price of $12.53 per share, for a total transaction of $31,325.00. Following the completion of the transaction, the director directly owned 30,549 shares in the company, valued at approximately $382,778.97. This trade represents a 8.91% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 3.70% of the stock is owned by company insiders.

Hedge Funds Weigh In On Medifast

Several institutional investors have recently added to or reduced their stakes in the company. BNP Paribas Financial Markets increased its stake in Medifast by 103.1% in the 3rd quarter. BNP Paribas Financial Markets now owns 2,338 shares of the specialty retailer’s stock worth $32,000 after acquiring an additional 1,187 shares during the last quarter. Quantbot Technologies LP bought a new position in shares of Medifast during the 3rd quarter valued at approximately $37,000. Intesa Sanpaolo Wealth Management purchased a new position in shares of Medifast in the fourth quarter valued at $47,000. State of Wyoming purchased a new position in shares of Medifast in the fourth quarter valued at $59,000. Finally, Strs Ohio bought a new stake in Medifast in the first quarter worth $78,000. Hedge funds and other institutional investors own 95.51% of the company’s stock.

About Medifast

Medifast, Inc (NYSE: MED) is a health and wellness company specializing in clinically supported weight-loss, weight-management and healthy living products and services. Through its OPTAVIA brand, the company offers a range of meal replacement products, snacks, supplements and coaching programs designed to support metabolic health and sustainable lifestyle changes. Medifast markets its products directly to consumers via a network of independent distributors—known as OPTAVIA Coaches—who provide personalized guidance and support throughout the client’s weight‐loss journey.

Founded in 1980 by William Vitale and headquartered in Baltimore, Maryland, Medifast has grown into a nationally recognized provider of nutrition and weight‐management solutions.